AACR CEO Warns Against Proposed NIH Budget Cuts
At the American Association for Cancer Research (AACR) 2026 annual meeting in San Diego, Revolution Medicines presented compelling Phase II data for its investigational KRASG12C inhibitor, RMC-6236, reinforcing its potential as a next-generation therapy for non-small cell lung cancer (NSCLC) and colorectal cancer. The findings, shared during a late-breaking abstract session, showed a confirmed objective response rate (ORR) of 48% in heavily pretreated patients with KRASG12C-mutant NSCLC who had progressed on prior chemotherapy and immunotherapy, with a median progression-free survival (PFS) of 8.2 months. These results build upon earlier Phase I data and position RMC-6236 as a significant contender in the rapidly evolving KRAS-targeted therapeutic landscape, particularly as resistance mechanisms to first- and second-generation inhibitors continue to emerge.
Key Clinical Takeaways:
- RMC-6236 demonstrated a 48% confirmed ORR and 8.2-month median PFS in KRASG12C-mutant NSCLC patients after failure of standard therapies.
- The drug exhibits a favorable safety profile, with dose-limiting toxicities occurring in less than 10% of participants, primarily manageable gastrointestinal and hepatic events.
- Ongoing Phase III trials (KNOCKOUT-206) are evaluating RMC-6236 in combination with pembrolizumab versus chemotherapy in first-line metastatic NSCLC, with primary readout expected in late 2027.
The clinical significance of targeting KRASG12C cannot be overstated. Historically deemed “undruggable,” the KRAS gene is mutated in approximately 13% of NSCLC cases and 3-5% of colorectal cancers in Western populations, making it one of the most prevalent oncogenic drivers in solid tumors. The G12C substitution accounts for roughly 40% of all KRAS mutations in lung adenocarcinoma, creating a substantial patient population amenable to allele-specific inhibition. Revolution Medicines’ approach with RMC-6236 involves a bifunctional molecule that covalently binds the KRASG12C switch-II pocket while simultaneously recruiting the E3 ubiquitin ligase complex to induce targeted protein degradation—a mechanism distinct from earlier inhibitors like sotorasib and adagrasib, which rely solely on occupancy-based blockade. This dual-action strategy aims to overcome both intrinsic and acquired resistance, including those mediated by RAS pathway reactivation or effector rewiring.
According to the primary source, the Phase II trial (NCT04699188) enrolled 129 patients with advanced solid tumors harboring KRASG12C mutations, including 86 with NSCLC and 29 with colorectal cancer. The study was funded by Revolution Medicines in collaboration with the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis under a cooperative agreement mechanism, with additional biomarker analysis supported by the Cancer Research UK Grand Challenge initiative. Pharmacodynamic data revealed sustained target suppression exceeding 90% at the recommended Phase II dose of 300 mg twice daily, correlating with tumor shrinkage in both lung and colorectal cohorts. Notably, among colorectal cancer patients, the ORR was 32% with a disease control rate (DCR) of 76%, suggesting activity even in a microenvironment historically resistant to monotherapy.
“What sets RMC-6236 apart is its ability to not just inhibit but eliminate the oncogenic KRAS protein, which may delay or prevent the emergence of resistance clones that plague current standard-of-care agents.”
Safety monitoring revealed no treatment-related deaths, with grade 3 or higher adverse events occurring in 18% of the cohort. The most common included elevated transaminases (ALT/AST, 12%), diarrhea (9%), and nausea (7%), most of which were reversible with dose interruption or symptomatic management. No cases of interstitial lung disease or QT prolongation were observed, addressing key safety concerns associated with other KRAS-targeted agents. These findings support the drug’s suitability for broader clinical application, including potential use in elderly or comorbid populations where tolerability is paramount.
Looking ahead, Revolution Medicines has initiated the global Phase III KNOCKOUT-206 trial (NCT05580341), a randomized, open-label study comparing RMC-6236 plus pembrolizumab against investigator’s choice of platinum-based chemotherapy in previously untreated, PD-L1-positive metastatic NSCLC with KRASG12C mutation. The trial aims to enroll 340 patients across 150 sites in North America, Europe, and Asia-Pacific, with co-primary endpoints of PFS and overall survival (OS). An interim analysis is planned for 2027, with final results anticipated by 2028. This study represents a critical inflection point—not only for the drug’s regulatory trajectory but also for defining whether KRASG12C-targeted therapy can achieve first-line superiority over chemotherapy-immunotherapy backbones in molecularly selected populations.
For clinicians managing patients with advanced NSCLC or gastrointestinal malignancies harboring KRASG12C mutations, integrating molecular profiling into routine diagnostic workflows remains essential. Institutions offering comprehensive genomic profiling—such as those accessible through verified molecular pathology laboratories—enable timely identification of actionable alterations and appropriate trial or therapy matching. Similarly, patients requiring multidisciplinary evaluation for complex gastrointestinal presentations may benefit from consultation with specialized gastrointestinal oncologists who are experienced in navigating biomarker-driven treatment algorithms and clinical trial enrollment. As therapeutic options expand, coordination between medical oncologists, molecular pathologists, and clinical trial coordinators becomes increasingly vital to ensure equitable access to precision medicine innovations.
While the excitement surrounding KRAS inhibition is justified, it is imperative to temper enthusiasm with scientific rigor. Long-term data on durability of response, mechanisms of acquired resistance to degraders, and real-world effectiveness across diverse populations remain outstanding questions. Equitable access to genomic testing and targeted therapies continues to be a systemic challenge, particularly in underserved communities where biomarker testing rates lag behind national averages. Addressing these gaps will require not only scientific advancement but also deliberate health policy and infrastructure investment.
The AACR 2026 findings underscore a transformative moment in oncology: what was once considered an intractable target is now yielding reproducible, clinically meaningful results through innovative molecular strategies. As the field moves toward combination regimens and earlier intervention, the imperative remains clear—innovation must be matched by accessibility, and scientific promise must be translated into equitable patient outcomes.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*